Ryvu has only about $7m in cash and equivalents but believes that a mixture of venture debt, milestones from partners and tapping the equity capital markets will provide the funds to advance RVU120 for acute myeloid leukemia and myelodysplastic syndrome.

The lipoprotein(a)-lowering antisense drug olpasiran reduced the cardiovascular disease risk factor Lp(a) by up to 101.1% relative to placebo. A Phase III trial will begin in December. 

While it is benefiting handsomely from the near 50-year low of the yen, Takeda said strong underlying growth for its mainstays in the fiscal first half was one factor behind its raised full-year forecast, and the Japanese major also sees a brighter long-term outlook for global blockbuster Entyvio.

A couple of trials for two investigational late-stage breast cancer candidates from AstraZeneca have each produced encouraging data for a novel drug class where rivals have previously hit clinical buffers.